Quest Diagnostics Inc. (DGX) News

Quest Diagnostics Inc. (DGX): $148.95

-0.12 (-0.08%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Filter DGX News Items

DGX News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

DGX News Highlights

  • DGX's 30 day story count now stands at 32.
  • Over the past 28 days, DGX's stories per day has been in a clear downtrend, falling by about 0.25 per day.
  • MA, LAB and NOV are the most mentioned tickers in articles about DGX.

Latest DGX News From Around the Web

Below are the latest news stories about QUEST DIAGNOSTICS INC that investors may wish to consider to help them evaluate DGX as an investment opportunity.

Quest Diagnostics Completes Acquisition of Outreach Lab Services Business of Summa Health

Quest Diagnostics (NYSE: DGX), the nation's leading provider of diagnostic information services, today announced it has completed its previously announced acquisition of select assets of LabCare Plus, the outreach laboratory services business of Summa Health, a large integrated health system. Additional financial terms were not disclosed.

Yahoo | November 28, 2022

Addressing Social Determinants of Health and Improving Access to Health Services and Resources

Addressing social determinants of health and improving access to health services and resources

Yahoo | November 22, 2022

The total return for Quest Diagnostics (NYSE:DGX) investors has risen faster than earnings growth over the last five years

Generally speaking the aim of active stock picking is to find companies that provide returns that are superior to the...

Yahoo | November 18, 2022

Quest Diagnostics To Plunge 16%? Here Are 5 Other Price Target Changes For Thursday

Citigroup cut Quest Diagnostics Incorporated (NYSE: DGX ) price target from $145 to $125. . Citigroup analyst Patrick Donnelly downgraded the stock from Neutral to Sell. Quest Diagnostics shares rose 0.9% to close at $149.27 on Wednesday. Deutsche Bank cut the price target on Target Corporation (NYSE: TGT ) from $183 to $144. Deutsche Bank analyst Paul Trussell downgraded the stock from Buy to Hold. Target shares fell 0.2% to $155.24 in pre-market trading. HC Wainwright & … Full story available on Benzinga.com

Benzinga | November 17, 2022

Quest Diagnostics downgraded to sell at Citi following recent stock upside (NYSE:DGX)

Citi has downgraded Quest Diagnostics (DGX) to sell from neutral as the stock has had a recent run-up in price.

Seeking Alpha | November 17, 2022

Improving Outcomes for the Leading Cause of Death in the US

New biomarkers offer pathways to prevention

Yahoo | November 16, 2022

ConferMED, through Grant from the Quest Diagnostics Foundation, now Providing Specialty eConsults to Front Line Primary Care Providers at Federally Qualified Health Centers in Five Key Metropolitan Areas

ConferMED, one of the nation's leading eConsult companies, announced today it is providing specialty eConsults to eligible Federally Qualified Health Centers (FQHCs) in cities serving close to 400,000 uninsured and underinsured patients through a $2.3M grant from the Quest Diagnostics Foundation. The grant is part of the foundation's Quest for Health Equity (Q4HE) initiative and is being provided to ConferMED's Advancing Health Equity Project to address a leading cause of health inequity: lack o

Yahoo | November 16, 2022

DermTech and Sonora Quest Laboratories Expand Access to Innovative Melanoma Detection Test

LA JOLLA, Calif. & PHOENIX, November 15, 2022--DermTech, Inc. (NASDAQ: DMTK) ("DermTech" or the "Company"), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today an agreement with Sonora Quest Laboratories (Sonora Quest), Arizona’s leading diagnostic laboratory, to expand access to enhanced melanoma detection. As a result of the agreement, Sonora Quest will be the exclusive laboratory in Arizona to offer the DermTech Melanoma Test to its vast network

Yahoo | November 15, 2022

Quest Diagnostics declares $0.66 dividend

Quest Diagnostics (DGX) declares $0.66/share quarterly dividend, in line with previous.Forward yield 1.76%Payable Feb. 1; for shareholders of record Jan. 18; ex-div Jan. 17.See DGX…

Seeking Alpha | November 14, 2022

Quest Diagnostics Declares Quarterly Cash Dividend

Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced that its Board of Directors declared a quarterly cash dividend of $0.66 per share, payable on February 1, 2023 to shareholders of record of Quest Diagnostics common stock on January 18, 2023.

Yahoo | November 14, 2022


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.7356 seconds.